New trial shows aspirin has no effect on dementia risk
But there’s just a hint of benefit that could be explored in bigger studies, the researchers say.
Tag: American Heart Association Scientific Sessions 2021
Rivaroxaban ‘beneficial’ after revascularisation for claudication
Further results from the VOYAGER-PAD trial show use of the agent reduces major cardiovascular events.
Early rhythm control ‘effective across AF types’
Patients with first-diagnosed AF tend to have the longest hospital spell, investigators find.
Antiplatelet combo benefits post-CABG ‘durable for five years’
Chinese researchers report five-year outcomes in a trial comparing dual and single antiplatelet therapies.
Omega-3 fails to make the grade for early COVID-19 therapy
Researchers report esults from a trial in 2000 Argentinian patients with early disease.
Control of hypertension disrupted during the pandemic: study
Large US study shows some health services handled patient care better than others, researcher says.
Empagliflozin ‘staves off hospital for patients with true HFpEF’
Fresh analysis of a pivotal heart failure trial highlights the drug's benefit in patients with a high degree of ejection fraction preservation.
Fitbit can detect silent AF: study
A new algorithm for detecting arrhythmia is before the US FDA for approval.
Simple incision ‘reduces postoperative AF’
Surgeons may have found a way to reduce two cardiac surgery complications with one snip.
Is the dream over for stem-cell therapy for HF?
The DREAM-HF trial failed to meet its primary endpoint, but the therapy was associated with better outcomes, researchers report.
